171 related articles for article (PubMed ID: 1937080)
1. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.
Khawly JA; Saloupis P; Hatchell DL; Machemer R
Graefes Arch Clin Exp Ophthalmol; 1991; 229(5):464-7. PubMed ID: 1937080
[TBL] [Abstract][Full Text] [Related]
2. The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy.
Chen EP; Steinhorst UH; Samsa GP; Saloupis PT; Hatchell DL
Invest Ophthalmol Vis Sci; 1992 Jun; 33(7):2160-4. PubMed ID: 1607226
[TBL] [Abstract][Full Text] [Related]
3. N,N-dimethyladriamycin for treatment of experimental proliferative vitreoretinopathy: efficacy and toxicity on the rabbit retina.
Steinhorst UH; Chen EP; Machemer R; Hatchell DL
Exp Eye Res; 1993 Apr; 56(4):489-95. PubMed ID: 8500561
[TBL] [Abstract][Full Text] [Related]
4. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye.
Steinhorst UH; Chen EP; Hatchell DL; Samsa GP; Saloupis PT; Westendorf J; Machemer R
Invest Ophthalmol Vis Sci; 1993 Apr; 34(5):1753-60. PubMed ID: 8473115
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy.
Kirmani M; Santana M; Sorgente N; Wiedemann P; Ryan SJ
Retina; 1983; 3(4):269-72. PubMed ID: 6201971
[TBL] [Abstract][Full Text] [Related]
6. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment.
Chandler DB; Hida T; Sheta S; Proia AD; Machemer R
Graefes Arch Clin Exp Ophthalmol; 1987; 225(4):259-65. PubMed ID: 3653718
[TBL] [Abstract][Full Text] [Related]
7. Effect of adriamycin on experimental proliferative vitreoretinopathy in the rabbit.
Sunalp MA; Wiedemann P; Sorgente N; Ryan SJ
Exp Eye Res; 1985 Jul; 41(1):105-15. PubMed ID: 4029281
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.
Nakagawa M; Refojo MF; Marin JF; Doi M; Tolentino FI
Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2388-95. PubMed ID: 7591628
[TBL] [Abstract][Full Text] [Related]
9. Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit.
Santana M; Wiedemann P; Kirmani M; Minckler DS; Patterson R; Sorgente N; Ryan SJ
Graefes Arch Clin Exp Ophthalmol; 1984; 221(5):210-3. PubMed ID: 6489768
[TBL] [Abstract][Full Text] [Related]
10. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy.
Chandler DB; Rozakis G; de Juan E; Machemer R
Am J Ophthalmol; 1985 Jun; 99(6):686-90. PubMed ID: 2409802
[TBL] [Abstract][Full Text] [Related]
11. Experimental model of proliferative vitreoretinopathy (PVR) in the vitrectomised eye: effect of silicone oil.
Lean JS; van der Zee WA; Ryan SJ
Br J Ophthalmol; 1984 May; 68(5):332-5. PubMed ID: 6712912
[TBL] [Abstract][Full Text] [Related]
12. Effects of cytotoxic drugs on proliferative vitreoretinopathy in the rabbit cell injection model.
Sunalp M; Wiedemann P; Sorgente N; Ryan SJ
Curr Eye Res; 1984 Apr; 3(4):619-23. PubMed ID: 6425019
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of experimental proliferative vitreoretinopathy in rabbits].
Kuriyama S; Ohuchi T; Okada M; Yamakawa R; Yoshimura N; Honda Y
Nippon Ganka Gakkai Zasshi; 1990 Sep; 94(9):792-8. PubMed ID: 2248164
[TBL] [Abstract][Full Text] [Related]
14. Taxol treatment of experimental proliferative vitreoretinopathy.
Daniels SA; Coonley KG; Yoshizumi MO
Graefes Arch Clin Exp Ophthalmol; 1990; 228(6):513-6. PubMed ID: 1979953
[TBL] [Abstract][Full Text] [Related]
15. Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo.
Wiedemann P; Sorgente N; Bekhor C; Patterson R; Tran T; Ryan SJ
Invest Ophthalmol Vis Sci; 1985 May; 26(5):719-25. PubMed ID: 3997421
[TBL] [Abstract][Full Text] [Related]
16. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy.
Wiedemann P; Leinung C; Hilgers RD; Heimann K
Graefes Arch Clin Exp Ophthalmol; 1991; 229(2):150-2. PubMed ID: 2044976
[TBL] [Abstract][Full Text] [Related]
17. The lack of an effect of intraocular steroids on irradiated fibroblasts in experimental proliferative vitreoretinopathy.
Chandler DB; Hida T; Rozakis G; Forbes VS; Machemer R
Graefes Arch Clin Exp Ophthalmol; 1992; 230(2):188-91. PubMed ID: 1577303
[TBL] [Abstract][Full Text] [Related]
18. Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy.
Wiedemann P; Lemmen K; Schmiedl R; Heimann K
Am J Ophthalmol; 1987 Jul; 104(1):10-4. PubMed ID: 3605276
[TBL] [Abstract][Full Text] [Related]
19. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy.
Moritera T; Ogura Y; Yoshimura N; Honda Y; Wada R; Hyon SH; Ikada Y
Invest Ophthalmol Vis Sci; 1992 Oct; 33(11):3125-30. PubMed ID: 1399416
[TBL] [Abstract][Full Text] [Related]
20. Regular silicone and fluorosilicone oil in the prevention of retinal detachment caused by experimental proliferative vitreoretinopathy.
Alghadyan A; Peyman GA; Fizer C; Tawakol M; Liu KR; Yue B; Peace JH
Int Ophthalmol; 1988 Jan; 11(3):171-4. PubMed ID: 3417389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
